Trial Profile
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Danvatirsen (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors MedImmune
- 26 Feb 2019 Status changed from active, no longer recruiting to completed.
- 14 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2018 Planned End Date changed from 11 Sep 2023 to 7 Nov 2023.